The use of bispecific antibodies (BsAb) before chimeric antigen receptor T-cell therapy (CAR-T) appeared to be a more optimal ...

The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...

ROCHESTER, N.Y. (WROC) — A groundbreaking Hodgkin lymphoma study from the University of Rochester Medical Center showed a 92% survival rate with fewer side effects and reduced radiation therapy use.

Monjuvi, Revlimid, and Rituxan reduced disease progression risk by 57% in relapsed/refractory follicular lymphoma patients compared to placebo plus Revlimid and Rituxan. The investigational regimen ...

Burkitt's lymphoma is a rare and aggressive blood cancer characterized by a translocation of the MYC gene. It occurs most ...

Stage 3 Hodgkin’s lymphoma either indicates lymphoma in the lymph nodes both above and below a person’s diaphragm or in the lymph nodes above the diaphragm and in the spleen. Doctors may also refer to ...

Stage 4 diffuse large B-cell lymphoma (DLBCL) is a rapidly growing lymphoma affecting at least one other organ outside the lymphatic system. Cancer is the unusual growth and spread of cells within the ...

NSHL is the most common type of Hodgkin’s lymphoma and mostly affects children and young adults. It’s highly curable with prompt treatment, so recognizing the symptoms is crucial. Hodgkin’s lymphoma ...